`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`_____________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_____________________
`
`
`ARGENTUM PHARMACEUTICALS LLC
`
`Petitioner
`
`v.
`
`CIPLA LIMITED
`
`Patent Owner
`
`_____________________
`
`Case No. IPR2017-00807
`
`U.S. Patent No. 8,168,620
`_____________________
`
`CIPLA LIMITED’S UPDATED MANDATORY NOTICES
`
`Mail Stop “PATENT BOARD”
`Patent Trial and Appeal Board
`U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`
`
`
`
`
`Cipla Limited’s Updated Mandatory Notices
`
`Patent Owner, Cipla Limited, hereby files updated mandatory notices
`
`pursuant to 37 C.F.R. § 42.8(a)(3).
`
`A. Real Party-in-Interest (37 C.F.R. § 42.8(b)(1))
`
`The real parties-in-interest are: Cipla Limited; Meda Pharmaceuticals Inc.;
`
`Meda AB; Mylan N.V.; Mylan Inc. (which is an indirect wholly owned subsidiary
`
`of Mylan N.V.); Mylan Pharmaceuticals, Inc. (which is a wholly owned subsidiary
`
`of Mylan Inc.); and Mylan Specialty L.P. (which is an indirect wholly owned
`
`subsidiary of Mylan N.V.).
`
`B. Related Matters (37 C.F.R. § 42.8(b)(2))
`
`(1) Meda Pharms. Inc. v. Apotex Inc., 14-cv-01453 (D. Del.); (2) Meda
`
`Pharms. Inc. v. Teva Pharms., 15-cv-00785 (D. Del.); and (3) Meda Pharms. Inc.
`
`v. Perrigo UK Finco Ltd., 16-cv-00794 (D. Del.).
`
`Patent Owner identifies the following patent application that claims or may
`
`claim the benefit of the priority of the filing date of U.S. Patent No. 8,168,620:
`
` U.S. Application No. 15/070,839 filed March 15, 2016 (pending).
`
`Patent Owner further identifies the following patent application assigned to
`
`Meda Pharmaceuticals Inc.:
`
` U.S. Application No. 13/284,836 filed October 28, 2011 (pending).
`
`Patent Owner does not concede that any of these applications would affect,
`
`or be affected by, a decision in the present inter partes review of U.S. Patent No.
`
`- 1 -
`
`
`
`
`
`Cipla Limited’s Updated Mandatory Notices
`
`8,168,620.
`
`C. Lead and Back-Up Counsel (37 C.F.R. § 42.8(b)(3))
`
`Patent Owner designates the following lead and back-up counsel:
`
`
`
`
`
`
`
` phone: 202.772.8520
`
`Lead Counsel: Dennies Varughese (Reg. No. 61,868) phone: 202.772.8805
`Back-up Counsel: Deborah A. Sterling (Reg. No. 62,732) phone: 202.772.8501
`Back-up Counsel: Adam C. LaRock (Reg. No. 64,681) phone: 202.772.8794
`(Pending pro hac vice admittance):
`Back-up Counsel: Uma N. Everett
`
`Address:
`
`
`
`STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
`1100 New York Avenue, NW
`Washington, DC 20005
`202.371.2600 (reception)
`202.371.2540 (facsimile)
`dvarughe-PTAB@skgf.com
` dsterlin-PTAB@skgf.com
`
`alarock-PTAB@skgf.com
`
`ueverett-PTAB@skgf.com
`
`
`
`
`
`
`
`
`
`
`
`- 2 -
`
`
`
`
`
`Cipla Limited’s Updated Mandatory Notices
`
`D.
`
`Service Information (37 C.F.R. § 42.8(b)(4))
`
`Please direct all correspondence regarding this proceeding to the lead
`
`counsel and back-up counsel at the addresses listed above.
`
`
`
`
`
`
`
` Respectfully Submitted,
`STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
`
`__________________________
`
` Dennies Varughese
` Lead Attorney for Patent Owner
` Registration No. 61,868
`
`
`
`Date: June 2, 2017
`
`
`
`
`
`1100 New York Avenue, NW
`Washington, DC 20005
`(202) 772-8501
`
`- 3 -
`
`
`
`
`
`
`
`CERTIFICATE OF SERVICE (37 C.F.R. §§ 42.6(e))
`
`The undersigned hereby certifies that the above-captioned “Cipla Limited’s
`
`Updated Mandatory Notices” was served in its entirety on June 2, 2017, upon the
`
`following parties via email:
`
`Michael R. Houston: mhouston@foley.com
`Joseph P. Meara: jmeara@foley.com
`James P. McParland: jmcparland@foley.com
`ARG-dymista@foley.com
`
`FOLEY & LARDNER LLP
`321 North Clark Street
`Suite 2800
`Chicago, IL 60654
`
`
`
`
`
`STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
`
`
`
`
`
`__________________________
`Dennies Varughese
`
`
`Date: June 2, 2017
`Lead Attorney for Patent Owner
`1100 New York Avenue, N.W.
`Registration No. 61,868
`Washington, D.C. 20005-3934
`(202) 371-2600
`
`
`
`
`
`
`
`